Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
31 Janvier 2024 - 2:00PM
Business Wire
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company with a primary
focus on leveraging its novel and proprietary CellFX Nanosecond
Pulsed Field (nsPFA) technology for the treatment of atrial
fibrillation, today announced that its nsPFA technology will be
featured in a podium presentation at the 29th Annual AF Symposium
in Boston, Massachusetts, on February 2, 2024 at 10:00am ET.
The session will include a presentation on the latest
developments in Nanosecond Pulsed Field (nsPFA) technology,
specifically highlighting the preliminary findings from the
Company’s CellFX nsPFA 360 Cardiac Catheter First-In-Human
Feasibility Study. Dr. Petr Neužil, Chief of Cardiology at Na
Homolce Hospital, Prague and Dr. Vivek Reddy, Director of Cardiac
Arrhythmia Services at Mount Sinai Hospital, New York will provide
an overview of their experience with the CellFX nsPFA 360 Cardiac
Catheter and discuss the potential clinical implications and impact
on the treatment of atrial fibrillation.
"I look forward to presenting one of our initial cases with this
promising technology at the AF Symposium and am honored to be part
of the team to perform the first-in-human procedures with the
CellFX nsPFA 360 Cardiac Catheter," said Dr. Vivek Reddy. "The
circumferential footprint and flexible structure of the 360 nsPFA
catheter has been extremely fast and versatile in these initial
procedures, setting it apart from many other PFA catheters. We look
forward to completing enrollment in this study to fully assess the
safety and durability of this next generation PFA technology."
Presentation Details: Session: Case Transmissions
Session 4 Title: Nanosecond Pulsed Field Ablation for AF
Presenters: Prof. Petr Neužil and Dr. Vivek Reddy Session Date and
Time: February 2, 2024 from 10:00 am – 12:30 pm ET
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company
committed to health innovation that has the potential to improve
the quality of life for patients. The Company’s proprietary CellFX
Nanosecond Pulsed Field (nsPFA) technology delivers nanosecond
pulses of electrical energy to non-thermally clear cells while
sparing adjacent noncellular tissue. The Company is actively
pursuing the development of its CellFX nsPFA technology for use in
the treatment of atrial fibrillation and in a select few other
markets where CellFX nsPFA could have a profound positive impact on
healthcare for both patients and providers.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA,
CellFX nsPFA and the stylized logos are among the trademarks and/or
registered trademarks of Pulse Biosciences, Inc. in the United
States and other countries.
Forward-Looking Statements
All statements in this press release that are not historical are
forward-looking statements, including, among other things,
statements relating to the effectiveness of the Company’s CellFX
nsPFA technology and CellFX System to non-thermally clear cells
while sparing adjacent non-cellular tissue, statements concerning
the Company’s expected product development efforts, such as
advancement of its CellFX nsPFA 360 Cardiac Catheter to treat
atrial fibrillation, whether faster than current thermal ablation
technologies or otherwise, statements concerning whether any
clinical study will show that the Company’s novel nsPFA mechanism
of action and catheter design will deliver fast and precise
ablations in cardiac tissue, statements concerning market
opportunities, customer adoption and future use of the CellFX
System to address a range of conditions such as atrial
fibrillation, statements concerning early clinical successes and
whether they are predictive of the safety and efficacy of any
medical device such as the CellFX nsPFA 360 Cardiac Catheter, Pulse
Biosciences’ expectations, whether stated or implied, regarding
whether the Company’s CellFX nsPFA technology will become a
disruptive treatment option for treating atrial fibrillation or any
other medical condition, and other future events. These statements
are not historical facts but rather are based on Pulse Biosciences’
current expectations, estimates, and projections regarding Pulse
Biosciences’ business, operations and other similar or related
factors. Words such as “may,” “will,” “could,” “would,” “should,”
“anticipate,” “predict,” “potential,” “continue,” “expects,”
“intends,” “plans,” “projects,” “believes,” “estimates,” and other
similar or related expressions are used to identify these
forward-looking statements, although not all forward-looking
statements contain these words. You should not place undue reliance
on forward-looking statements because they involve known and
unknown risks, uncertainties, and assumptions that are difficult or
impossible to predict and, in some cases, beyond Pulse Biosciences’
control. Actual results may differ materially from those in the
forward-looking statements as a result of a number of factors,
including those described in Pulse Biosciences’ filings with the
Securities and Exchange Commission. Pulse Biosciences undertakes no
obligation to revise or update information in this release to
reflect events or circumstances in the future, even if new
information becomes available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240131411137/en/
Investor Contacts: Pulse Biosciences Kevin Danahy,
President and CEO 510.241.1077 IR@pulsebiosciences.com
or Gilmartin Group Philip Trip Taylor 415.937.5406
philip@gilmartinir.com
Pulse Biosciences (NASDAQ:PLSE)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Pulse Biosciences (NASDAQ:PLSE)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024